Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
August 19, 2008

AstraZeneca Taps Melior Discovery Platform

  • AstraZeneca plans to use Melior Discovery’s theraTRACE® discovery platform to evaluate selected compounds. “Melior will be providing a comprehensive in vivo profile of all of these compounds,” says Andrew Reaume, president and CEO of Melior.

    The firm developed this technology of multiplexed in vivo disease models to uncover new indications for existing pharmaceutical compounds. Melior believes that the ideal molecules to enter the theraTRACE® platform are mid- to late-stage clinical compounds previously discontinued for reasons other than safety.